Financial Performance - Operating revenue for the first nine months of 2024 was CNY 108.70 million, down 17.20% from CNY 131.28 million in the same period of 2023[5] - Net profit attributable to shareholders for the first nine months of 2024 was CNY 21.65 million, a decline of 42.17% from CNY 37.44 million year-on-year[5] - The company reported a basic earnings per share of CNY 0.24 for the first nine months of 2024, down 41.46% from CNY 0.41 in the same period of 2023[5] - Total operating revenue for the first nine months of 2024 was CNY 108,698,472.95, a decrease of 17.2% compared to CNY 131,282,869.50 in the same period of 2023[25] - The total profit for the first nine months of 2024 was approximately ¥20.08 million, a decrease of 60.5% from ¥50.83 million in the same period of 2023[27] - The company’s total comprehensive income attributable to the parent company for the first nine months of 2024 was approximately ¥21.65 million, compared to ¥37.44 million in 2023[28] Cash Flow and Liquidity - Cash flow from operating activities for the first nine months of 2024 was CNY 23.25 million, a decrease of 29.43% compared to CNY 32.95 million in the previous year[5] - Operating cash flow for the first nine months of 2024 was CNY 23,252,885.32, a decrease of 29.5% from CNY 32,948,415.96 in the same period of 2023[30] - Cash inflow from operating activities for the parent company was CNY 121,250,222.05, down from CNY 160,164,272.14 in the same period last year, reflecting a decrease of 24.3%[31] - The parent company reported a net cash flow from operating activities of CNY 12,738,423.51, down 39.8% from CNY 21,083,442.98 in 2023[32] - The company experienced a net increase in cash and cash equivalents of CNY 21,170,790.58, recovering from a decrease of CNY -305,701,643.02 in the same period last year[32] Assets and Liabilities - Total assets as of September 30, 2024, amounted to CNY 608.62 million, a decrease of 0.43% compared to CNY 611.24 million at the end of 2023[5] - The company’s total liabilities to assets ratio increased to 9.16% in the consolidated statement, up from 7.32% at the end of 2023[5] - The total liabilities of the company as of September 30, 2024, were CNY 55,771,626.34, compared to CNY 42,485,404.25 at the end of 2023, indicating an increase of about 31.2%[20] - The total liabilities as of September 30, 2024, were CNY 39,845,501.39, an increase from CNY 33,566,852.78, indicating potential leverage growth[23] - The company has no short-term borrowings as of September 30, 2024, maintaining a debt-free status in this category[20] Shareholder Information - The total number of unrestricted shares at the end of the reporting period is 44,584,441, accounting for 48.72% of the total share capital[9] - The number of restricted shares is 46,931,500, representing 51.28% of the total share capital[9] - The largest shareholder, Zhou Fang, holds 22,393,571 shares, which is 24.47% of the total shares[11] - The second-largest shareholder, Xiao Changjin, holds 14,486,500 shares, accounting for 15.83%[11] - The total number of shareholders holding more than 5% of shares is 10, with a combined holding of 53,568,449 shares, or 58.53%[11] Investment Activities - The company recorded a 116.76% increase in net cash flow from investing activities, totaling CNY 44.37 million, primarily due to the redemption of previously purchased certificates[7] - Cash inflow from investment activities increased to CNY 712,490,370.69 in 2024, up from CNY 599,155,622.67 in 2023, representing an increase of 18.9%[30] - Net cash flow from investment activities was CNY 44,370,616.09, a significant recovery from a negative cash flow of CNY -264,734,769.20 in the previous year[30] - Cash outflow for investment activities was CNY 654,570,416.54, a decrease from CNY 853,247,139.74 in the previous year, indicating a reduction of 23.3%[32] Research and Development - Research and development expenses increased to CNY 14,030,100.63 from CNY 13,057,607.36, indicating a continued focus on innovation[25] - Research and development expenses for the first nine months of 2024 were approximately ¥10.99 million, slightly up from ¥10.32 million in 2023[27] Other Information - The company completed the acquisition of a 55% stake in Afus, resulting in goodwill of CNY 6.87 million[6] - The company has approved share buyback plans, with amounts disclosed for specific transactions[14] - The company plans to use idle raised funds for cash management, with a limit of up to RMB 250 million[15] - There were no significant legal disputes or external guarantees during the reporting period[14] - The company has not reported any major asset restructuring or related party transactions[14]
新芝生物(430685) - 2024 Q3 - 季度财报